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patients, and 1.4% for blacks (P .0002). There was a longer operating time
(P  .001) and total length of stay (P  .001), more postoperative
pneumonias (P  .0049), unplanned intubations (P  .001), ventilator
dependence (P  .001), cardiac arrests (P  .001), bleeding requiring
transfusions (P  .0024), and returns to the operating room (P  .0021)
among black patients. Multivariate logistic regression identified black race as an
independent risk factor for 30-day mortality (relative risk, 1.9;P .0007). Black
patients also had more in-hospital deaths than white patients (73.7% vs 43.1%,
P .001). The rate of postdischarge strokes did not differ between the groups:
36.4% of all strokes occurred after discharge at a mean of 8.3 days and 54.3% of
deaths occurred after discharge at a mean of 11 days.
Conclusions: Black race is identified as an independent risk factor for
30-day mortality after CEA. A significant proportion of strokes and deaths
occur after discharge in both racial groups evaluated.
Progression of Asymptomatic Carotid Stenosis Despite Optimal Med-
ical Therapy
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Garg, Karen Furie, Richard Cambria. Massachusetts General Hospital,
Boston, Mass
Introduction and objectives: Despite level 1 evidence in support of
carotid endarterectomy (CEA) vs medical therapy in selected asymptomatic
patients, an alternative posture is that optimal medical therapy (OMT) has
not been adequately studied and that such OMT has reduced stroke risk to
levels wherein CEA is no longer justified. The goal of this study was to
determine the natural history of patients with asymptomatic moderate
(50%-69%) carotid stenosis (AMCS) in a contemporary cohort as a function
of their associated medical therapy.
Methods: Patients with AMCS determined by duplex ultrasound
(DUS) imaging from 2005 to 2006 were identified in our hospital database.
Patients were included in the cohort if they had at least one additional DUS
during the 6-year follow-up interval. Patient characteristics, including med-
ication history and lipid levels, were collected. Patients were considered to
have OMT if they were on aspirin and a statin with a low-density lipoprotein
(LDL) level100 mg/dL. Study end points included progression of carotid
disease by DUS (70%-100%), development of ipsilateral neurologic symp-
toms (stroke/transient ischemic attack), and death.
Results: There were 906 carotids in 801 patients in the study cohort.
The average age was 72.5 years, 77.3% had hypertension, 59.7% had
coronary artery disease (CAD), and 84% were on a statin. The LDL choles-
terol level was always normal (100) in 56.4%, and 29.4% had OMT. The
5-year actuarial outcomes are detailed in the Table. Ipsilateral symptoms
developed in 97 patients during follow-up (58% of these were strokes).
Multivariate predictors of disease progression were chronic kidney disease
(hazard ratio [HR], 2.14; confidence interval [CI], 1.22-3.76; P  .0008),
and statin use (HR, 1.59; CI, 1.0-2.53; P .0049). The multivariate models
of symptom development and survival showed that statin use was protective
for both (symptoms: HR, .046; CI, .026-0.79; P  .0005; survival: HR,
.050; CI, .034-0.73; P  .00004).
Conclusions: OMT failed to prevent disease progression or develop-
ment of ipsilateral symptoms in patients with AMCS.
Table. Five-year outcomes
Variable
Cohort, %
(n  906)
OMT, %
P
Yes
(n  266)
No
(n  640)
Survival 75.4 75.4 75.4 .86
Freedom from disease
progression 61.5 60.6 61.7 .37
Freedom from symptoms 87 85 87.9 .17
Freedom from ipsilateral
CEA/CAS 71.7 67.5 73.6 .10
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Introduction and objectives: As renal transplantation has been per-
formed with increased frequency, interventions to preserve graft function and
integrity have been steadily increasing. This study examines the outcomes of
endovascular therapy based on indication for renal allograft salvage.
Methods: A prospective transplant registry was queried for all patients
undergoing endovascular interventions for transplant allograft salvage from
2002 to 2011. Demographics, perioperative data, and transplant function
outcomes were extracted and analyzed.
Results: Among 34 renal transplant recipients who underwent endo-
vascular interventions for graft salvage, the mean age was 48.2 years (18-74
years), and 62% were men. The indications for intervention included wors-
ening serum creatinine (n  15), renovascular hypertension (n  11), and
structural abnormalities identified on noninvasive imaging (n 8). Translu-
minal angioplasty, with or without stenting, was done in 26 patients: 14
(41.2%) with significant transplant stenosis, 11 (32.4%) with peripheral
arterial disease (PAD) in proximal iliac vessels, and one with iliac dissection.
Five arteriovenous fistulae and two pseudoaneurysms required emboliza-
tion. One patient had deep venous thrombosis causing obstruction of
allograft outflow requiring lysis. There were no periprocedural deaths, and
30-day morbidity was 17.6%. Of patients with worsening renal function,
67% had improvement or stabilization of their renal function. Interestingly,
only 36% of patients with renovascular hypertension showed improvement.
Mean follow-up was 4.2 years. There were no significant differences in
transplant allograft survival over the duration of follow-up based on indica-
tion for endovascular intervention (Fig; log-rank test, P  .03).
Conclusions: Endovascular salvage of renal allograft transplants can be
safely done for various indications, although patients with renovascular
hypertension were less likely to improve. Despite differences in symptomatic
outcome, the indication for initial intervention does not significantly influ-
ence the long-term transplant graft survival.
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Introduction and objectives: Secondary interventions for restenosis
after renal artery angioplasty and stenting are commonly performed, despite
limited data on their effectiveness. This study was designed to evaluate
whether successful outcomes are achieved in patients after endovascular
treatment of recurrent renal artery stenosis (RAS).
Methods: We conducted a retrospective review of all patients who
underwent renal artery angioplasty or stenting, or both, for renovascular
hypertension between 2001 and 2011 at Dartmouth-Hitchcock Medical
Center. We compared the clinical effectiveness of secondary vs primary
interventions. Nonparametric models were used to identify factors associ-
ated with successful outcomes, as measured by changes in blood pressure,
estimated glomerular filtration rate (eGFR), and number of antihypertensive
medications.
Results: Thirty-nine patients (54 renal arteries) underwent secondary
interventions for recurrent RAS, and 180 patients (180 arteries) underwent
primary intervention. There were no significant differences between patients
undergoing primary vs secondary interventions with respect to preoperative
medication usage (including antihypertensive, antiplatelet or statin medica-
tions), comorbid conditions, or blood pressure. Primary and secondary
interventions were both completed using a similar proportion of bare-metal
stents (90%), with no difference in procedural complications or technical
success. At a mean follow-up of 23 months (range, 1-128 months), similar
improvements in renal function were found between patients undergoing
primary and secondary interventions (Fig). There were no differences in
number of antihypertensive medications, overall blood pressure manage-
ment, or overall survival.
Fig.
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